Author’s response to reviews

Title: Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer

Authors:

Shakeel Sumodhee (shakeel.sumodhee@nice.unicancer.fr)
Pierre-Yves Bondiau (pierre-yves.bondiau@nice.unicancer.fr)
Michel Poudenx (michel.poudenxx@nice.unicancer.fr)
Charlotte Cohen (cohen.c@chu-nice.fr)
Arash Naghavi (aonaghavi@gmail.com)
Bernard Padovani (padovani.b@chu-nice.fr)
Daniel Maneval (daniel.maneval@nice.unicancer.fr)
Jocelyn Gal (jocelyn.gal@nice.unicancer.fr)
Axel Leysalle (axel.leysalle@nice.unicancer.fr)
Hannah Ghalloussi (hannah.ghalloussi@nice.unicancer.fr)
Josiane Otto (josiane.otto@nice.unicancer.fr)
Jérôme Doyen (jerome.doyen@nice.unicancer.fr)

Version: 1 Date: 21 Mar 2019

Author’s response to reviews:

Chalisa Iamsrithong
Editor
BMC Cancer

Nice, March 21st, 2019

Dear Chalisa Iamsrithong,
Thank you for handling this manuscript. We re-submit the revised manuscript for publication in BMC Cancer entitled “Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer”.

We thank the reviewers for their very helpful comments and suggestions. Please find below how we have addressed their comments.

1. Please include a statement on ethics approval and consent to participate in the “Ethics approval and consent to participate” section of the Declarations. Please include the full name of the ethics committee (and the institute to which it belongs to) that approved the study and the committee’s reference number if appropriate.

We have detailed the statement on ethics approval and consent to participate as follows: “Our protocol was approved by the Institutional Review Board of Antoine Lacassagne Cancer Centre (MR001) which approved the ethical aspect of the protocol. The board waived the requirement for informed consents because this study was retrospective.” (line 356)

2. Please provide a list of all the abbreviations used in the manuscript. This list should be placed just before the Declarations section.

We placed the list of all the abbreviations just before the Declarations section according to your recommendation.

3. Please move the Figure and Table legends so that they are placed just after the References.

We moved the Figure and Table legends after the References according to your recommendation.

4. Please rename “Materials and Methods” to “Methods.”

We renamed “Materials and Methods” to “Methods” (line 88).